Summary:
- This article discusses a new drug candidate that may help slow down the progression of Alzheimer's disease in some high-risk patients.
- The drug, called donanemab, was tested in a clinical trial and showed promising results in reducing cognitive decline and brain shrinkage in individuals with early-stage Alzheimer's.
- The findings suggest that this drug could potentially be a valuable treatment option for those at high risk of developing Alzheimer's, though further research is still needed to confirm its long-term efficacy and safety.